| Comparative effectiveness of gemcitabine plus nab-paclitaxel and FOLFIRINOX in the first-line setting of metastatic pancreatic cancer: a systematic review and meta-analysis S Pusceddu, M Ghidini, M Torchio, F Corti, G Tomasello, M Niger, N Prinzi, ... Cancers 11 (4), 484, 2019 | 101 | 2019 |
| Targeting the PI3K/AKT/mTOR pathway in biliary tract cancers: A review of current evidences and future perspectives F Corti, F Nichetti, A Raimondi, M Niger, N Prinzi, M Torchio, E Tamborini, ... Cancer treatment reviews 72, 45-55, 2019 | 101 | 2019 |
| Diet and supplements in cancer prevention and treatment: Clinical evidences and future perspectives C Vernieri, F Nichetti, A Raimondi, S Pusceddu, M Platania, F Berrino, ... Critical reviews in oncology/hematology 123, 57-73, 2018 | 67 | 2018 |
| Trifluridine/Tipiracil (TAS‐102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program C Cremolini, D Rossini, E Martinelli, F Pietrantonio, S Lonardi, S Noventa, ... The Oncologist 23 (10), 1178-1187, 2018 | 58 | 2018 |
| Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: results from the expanded access program A Prelaj, A Bottiglieri, C Proto, GL Russo, D Signorelli, R Ferrara, G Galli, ... European Journal of Cancer 149, 235-248, 2021 | 57 | 2021 |
| Is there an interplay between immune checkpoint inhibitors, thromboprophylactic treatments and thromboembolic events? Mechanisms and impact in non-small cell lung cancer patients F Nichetti, F Ligorio, E Zattarin, D Signorelli, A Prelaj, C Proto, G Galli, ... Cancers 12 (1), 67, 2019 | 49 | 2019 |
| Role of MGMT as biomarker in colorectal cancer A Inno, G Fanetti, M Di Bartolomeo, S Gori, C Maggi, M Cirillo, R Iacovelli, ... World Journal of Clinical Cases: WJCC 2 (12), 835, 2014 | 42 | 2014 |
| Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical … C Vernieri, F Corti, F Nichetti, F Ligorio, S Manglaviti, E Zattarin, CG Rea, ... Breast Cancer Research 22, 1-13, 2020 | 37 | 2020 |
| Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation F Morano, S Corallo, M Niger, L Barault, M Milione, R Berenato, R Moretto, ... Annals of Oncology 29 (8), 1800-1806, 2018 | 37 | 2018 |
| Combination of immunotherapy and brain radiotherapy in metastatic melanoma: a retrospective analysis G Galli, S Cavalieri, L Di Guardo, C Cimminiello, F Nichetti, F Corti, ... Oncology research and treatment 42 (4), 182-189, 2019 | 30 | 2019 |
| Clinical implications for pro-GRP in small cell lung cancer. A single center experience S Cavalieri, D Morelli, A Martinetti, G Galli, F Nichetti, F de Braud, ... The International Journal of Biological Markers 33 (1), 55-61, 2018 | 29 | 2018 |
| Thrombin generation predicts early recurrence in breast cancer patients M Marchetti, C Giaccherini, G Masci, C Verzeroli, L Russo, L Celio, ... Journal of Thrombosis and Haemostasis 18 (9), 2220-2231, 2020 | 25 | 2020 |
| Is a pharmacogenomic panel useful to estimate the risk of oxaliplatin-related neurotoxicity in colorectal cancer patients? F Nichetti, FS Falvella, R Miceli, S Cheli, R Gaetano, G Fucà, G Infante, ... The Pharmacogenomics Journal 19 (5), 465-472, 2019 | 23 | 2019 |
| Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real‐world data M Rimini, L Fornaro, S Lonardi, M Niger, D Lavacchi, T Pressiani, ... Liver International 43 (8), 1803-1812, 2023 | 22 | 2023 |
| Systemic treatment of patients with gastrointestinal cancers during the COVID-19 outbreak: COVID-19-adapted recommendations of the National Cancer Institute of Milan F Pietrantonio, F Morano, M Niger, S Corallo, M Antista, A Raimondi, ... Clinical Colorectal Cancer 19 (3), 156-164, 2020 | 21 | 2020 |
| A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors S Pusceddu, F Barretta, A Trama, L Botta, M Milione, R Buzzoni, ... Endocrine-Related Cancer 25 (6), 607-618, 2018 | 21 | 2018 |
| Genomic markers of resistance to targeted treatments in gastric cancer: potential new treatment strategies A Raimondi, F Nichetti, G Peverelli, MD Bartolomeo, FD Braud, ... Pharmacogenomics 19 (13), 1047-1068, 2018 | 19 | 2018 |
| The role of mesothelin as a diagnostic and therapeutic target in pancreatic ductal adenocarcinoma: a comprehensive review F Nichetti, A Marra, F Corti, A Guidi, A Raimondi, N Prinzi, F de Braud, ... Targeted oncology 13, 333-351, 2018 | 19 | 2018 |
| COVID-19 risk for patients undergoing anticancer treatment at the outpatient clinic of the National Cancer Institute of Milan: The COVINT study F Nichetti, M Bini, M Ambrosini, A Ottini, A Rametta, R Leporati, D Polastri, ... ESMO open 5 (Suppl 3), 2020 | 16 | 2020 |
| One size does not fit all for pancreatic cancers: A review on rare histologies and therapeutic approaches M Niger, M Prisciandaro, M Antista, MAT Monica, L Cattaneo, N Prinzi, ... World journal of gastrointestinal oncology 12 (8), 833, 2020 | 14 | 2020 |
Filippo de BraudFull Professor of Medical Oncology and Director of the School of Specialization in Medical OncologyVerified email at unimi.it
